Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SyntaraFRA:UUDA -4.76% EV-to-OCF is -3.37 as of Aug. 31, 2026. The stock has 2 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Syntara ranks better than 74.85% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Syntara's Enterprise Value is €22.26 Mil.
Syntara's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-6.60 Mil. Therefore, Syntara's EV-to-OCF for today is -3.37.
The historical rank and industry rank for Syntara's EV-to-OCF or its related term are showing as below:
FRA:UUDA'
s EV-to-OCF Range Over the Past 10 Years
Min: -6.67 Med: -1.91 Max: 15.19
Current: -3.09
During the past 13 years, the highest EV-to-OCF of Syntara was 15.19. The lowest was -6.67. And the median was -1.91.
FRA:UUDA's EV-to-OCF is ranked better than 74.85% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.55
vs FRA:UUDA: -3.09
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Syntara's share price for today is €0.01.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Syntara's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.004.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Syntara EV-to-OCF Related Terms
Syntara EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Syntara's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Syntara's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syntara EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syntara's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Syntara's EV-to-OCF falls into.
Syntara's current Enterprise Value is €22.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Syntara's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-6.60 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Syntara (FRA:UUDA) has a EV-to-OCF of -3.37 as of Aug. 31, 2026. According to the industry distribution chart, Syntara ranks #253 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 25.1%.
Is Syntara's EV-to-OCF too high?
Syntara's current EV-to-OCF is -3.37. Based on the distribution chart, Syntara ranks #253 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Syntara's EV-to-OCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Syntara ranks #253 out of 1006 companies for EV-to-OCF. This puts Syntara in the upper half of its industry. The industry median EV-to-OCF is 10.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.55, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syntara's current EV-to-OCF is -3.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syntara stock overvalued right now?
Based on GuruFocus' analysis, Syntara (FRA:UUDA) is currently considered Possible Value Trap. The stock's GF Value™ is €0.02, compared to a current price of €0.01 — trading 50% below its estimated fair value. The current EV-to-OCF is -3.37. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Syntara (FRA:UUDA), the current EV-to-OCF is -3.37 as of Aug. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring and neuroinflammation.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:UUDA has been successfully added to your 
